Resolutum Global Leverages Medrio To Succeed In A Complex Phase 1 Oncology Study

Resolutum Global was tasked with completing a Phase 1 oncology study. Each of the study’s 28 patients had repeating alternate treatment cycles, with an average of 5 cycles per patient at a duration of 21 days per cycle. This design enabled the researchers to make modifications based on how the patients reacted to the oncology treatment. But as Moses Mwangi, Managing Director at Resolutum, notes, “the alternation of the treatment cycles brought a significant degree of complexity to this oncology study.”

That complexity was not the only challenge that Resolutum faced, as this was a rescue study that was already in progress over four years at three sites. There was significant pressure from the sponsor to Resolutum not to duplicate the completed tasks such as setup, data collection, and cleaning, as the sponsor had already made a large investment in getting the study up and running with the first provider. Rapid onboarding, then, was the name of the game – Resolutum would need to get a handle on the study, and on their eClinical technology resources, without costing the sponsor more time and budget.

This case study explains how by leveraging Medrio, they were able to succeed in this task and deliver satisfaction to the study sponsor.